Clay Thorp
CIK 1592380 · last filed 2025-02-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CLSD price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
280 S. MANGUM ST., SUITE 350
DURHAM, NC 27701
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Clearside Biomedical, Inc. (CLSD) Delisted | Director | 248,079 | $0.35 | $87.2K | $17.97M | 33 | 2025-02-24 |
| PhaseBio Pharmaceuticals Inc (PHAS) Delisted | Director | 48,375 | $0.07 | $3.4K | $1.51M | 12 | 2022-05-20 |
| Vigil Neuroscience, Inc. (VIGL) Delisted | Director | 1,544,137 | $8.05 | $12.43M | $3.84M | 3 | 2022-05-17 |
Recent Filings · Page 3 of 5
49 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-05 | PhaseBio Pharmaceuticals Inc (PHAS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-11-26 | Clearside Biomedical, Inc. (CLSD) Delisted | Grant (A) | +1,518,026 | $1.60M | EDGAR |
| 2019-07-03 | PhaseBio Pharmaceuticals Inc (PHAS) Delisted | Sell (S) | −2,908 | -$40.7K | EDGAR |
| 2019-06-24 | Clearside Biomedical, Inc. (CLSD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-20 | PhaseBio Pharmaceuticals Inc (PHAS) Delisted | Sell (S) | −400 | -$5.6K | EDGAR |
| 2019-05-13 | PhaseBio Pharmaceuticals Inc (PHAS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-03-01 | PhaseBio Pharmaceuticals Inc (PHAS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-12-06 | PhaseBio Pharmaceuticals Inc (PHAS) Delisted | Buy (P) | +4,000 | $12.5K | EDGAR |
| 2018-12-06 | Clearside Biomedical, Inc. (CLSD) Delisted | Buy (P) | +8,000 | $10.9K | EDGAR |
| 2018-10-24 | PhaseBio Pharmaceuticals Inc (PHAS) Delisted | Mixed | +2,458,049 | $1.50M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.